The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Apollo: pomalidomide plus dexamethasone, with/without daratumumab in R/R MM
Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, discusses the initial results of the APOLLO trial, a Phase III study (NCT03180736) of subcutaneous daratumumab (dara) plus pomalidomide and dexamethasone (Pd), compared to Pd alone in relapsed/refractory multiple myeloma. Dara is an anti-CD38 antibody, shown in earlier studies to establish deep responses in combination with pomalidomide. The data supported the use of D-Pd as an effective treatment for relapsed/refractory myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Transcript
Another trial that I would like to discuss is the APOLLO trial. The APOLLO trial has been performed in the European Myeloma Network. It is a trial in relapsed/refractory patients with multiple myeloma. The treatments in this randomized trial consisted of pomalidomide and dexamethasone with daratumumab or without daratumumab. The primary endpoint was progression-free survival. In the analysis that was done and submitted to ASH, it’s also observed that the response rate is significantly higher in patients receiving dara + pom-dex...
Another trial that I would like to discuss is the APOLLO trial. The APOLLO trial has been performed in the European Myeloma Network. It is a trial in relapsed/refractory patients with multiple myeloma. The treatments in this randomized trial consisted of pomalidomide and dexamethasone with daratumumab or without daratumumab. The primary endpoint was progression-free survival. In the analysis that was done and submitted to ASH, it’s also observed that the response rate is significantly higher in patients receiving dara + pom-dex. Also, a second observation was that progression-free survival is better. We also observed MRD negativity in patients. That was four times higher than in patients without daratumumab, 9 against 2%. This trial just had its first analysis. The results are very promising. They opened the way to treat patients in relapse/refractory situation with dara + pomalidomide and dexamethasone. We need longer follow-up to make any conclusions about the overall survival.
Read more...
